Field Name	Field Description
Prior Authorization	Veklury (remdesivir) / remdesivir
Group Description	
Drugs	Veklury (remdesivir), <u>remdesivir</u>
Covered Uses	Medically accepted indications are defined using the following sources: the
	Food and Drug Administration (FDA), Micromedex, American Hospital
	Formulary Service (AHFS), United States Pharmacopeia Drug Information for
	the Healthcare Professional (USP DI), and the Drug Package Insert (PPI).
Exclusion Criteria	N/A
Required Medical	See "Other Criteria"
Information	
Age Restrictions	N/A
Prescriber	N/A
Restrictions	
Coverage Duration	Labeled Use: 10 days Per FDA label
Other Criteria	**Drug is being requested through the member's medical benefit**
	Labeled Use: Veklury/remdesivir will be approved when all of the following criteria are met: • Diagnosis of COVID-19 • Patient is ≥12 years of age • Patient weighs at least 40kg • Patient is hospitalized • Attestation that provider is not requesting reimbursement for ingredient cost of drug when drug is provided by U.S. government at no charge.
Revision/Review Date 11/2020 1/2022	For uses related to the Emergency Use Authorization: Refer to the "Emergency Use Authorization (EUA) Drugs for COVID-19" policy Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.